Management of Atrial Fibrillation in Heart Failure
Introduction to Guideline Recommendations
- The European Society of Cardiology recommends against the use of diltiazem and verapamil in patients with heart failure with reduced ejection fraction (HFrEF), as they increase the risk of heart failure worsening and hospitalization, with a Class III recommendation (harm) 1, 2, 3.
Preferred Agents for Rate Control
- For acute rate control in heart failure patients with atrial fibrillation, the American Heart Association recommends IV digoxin or amiodarone, with a Class I, Level B recommendation 6, 7.
- IV amiodarone can be useful to control heart rate when other measures are unsuccessful or contraindicated, with a Class IIa recommendation, according to the American College of Cardiology 8, 6.
Safety and Efficacy of Amiodarone
- Amiodarone has been associated with neutral effects on survival and may actually increase left ventricular ejection fraction (LVEF) and decrease worsening heart failure incidence 4, 5.
- Amiodarone provides both rate control and rhythm control, which is particularly valuable in patients who have failed beta-blocker therapy alone 9.
- Amiodarone has minimal negative inotropic effects compared to other antiarrhythmics, making it safer in severe left ventricular dysfunction 4, 5.
Considerations for Liver Injury
- The patient's significant liver injury is a major concern with amiodarone, as hepatotoxicity is a known side effect, but the acute hemodynamic compromise from using diltiazem in severe HFrEF poses a more immediate mortality risk 4, 5, 1.
- If the liver injury is severe enough to absolutely contraindicate amiodarone, consider IV digoxin as an alternative for acute rate control, though it works more slowly 6, 7.